超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

以色列Compugen
Compugen 成立于1993年，其宗旨是通過計算機技術同生物學和醫學的結合，發現和開發新藥。此公司的優勢是具有雄厚的多學科基礎，其團隊由數學家、計算機學家、物理學家、化學家和分子生物學家組成，主要業務是用計算機技術分析和解釋生物學現象和數據，加速基因組學、蛋白質組學和其他生物學數據的處理，研究基因組學、功能基因組學和蛋白質組學，研發針對癌癥、免疫缺陷和神經病的生物技術藥物、藥物靶點和診斷標記。

Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industries under milestone and revenue sharing agreements. The Company’s increasing inventory of powerful and proprietary discovery platforms is enabling the predictive discovery – field after field – of numerous therapeutic and diagnostic product candidates. These discovery platforms are based on the Company’s decade-long focus on the predictive understanding of important biological phenomena at the molecular level. Compugen’s current collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate – Evogene Ltd. (TASE: EVGN.TA) – to utilize the Company’s in silico predictive discovery capabilities in the agricultural biotechnology field. 

Compugen has been publicly traded on Nasdaq (NASDAQ: CGEN) since August 2000 and on the Tel Aviv Stock Exchange since January 2002.